Risk factor
Resilient to price shocks
Profitability factor
Favourable analyst view
About
Shenzhen Weiguang Biological Products Co., Ltd. is a Chinese enterprise primarily dedicated to the entire lifecycle of blood products, encompassing their research, development, manufacturing, and distribution within the domestic market. Its comprehensive portfolio features a range of crucial blood-derived therapies, including human albumin, various intravenous immunoglobulin preparations (such as pH4 and its freeze-dried counterpart), general human immunoglobulin, and specific immunoglobulins targeting conditions like hepatitis B, rabies, and tetanus. Additionally, it provides histamine human immunoglobulin and human fibrinogen. These offerings collectively represent nine distinct product types, available in twenty-one different specifications. Established in 1985, the firm maintains its headquarters in Shenzhen, China.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value
Target Price
The average target price of 002880.SZ is 32.0 and suggests 51.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to